ARTICLE | Finance
Pandion’s immune-regulating platform attracts $80M B round
Pandion’s immune effectors can be mixed and matched with tissue-tethering antibodies, providing partnership opportunities across different diseases
April 1, 2020 11:23 AM UTC
Pandion raised $80 million in a series B round, triggered by a pancreas-focused partnership with Astellas and the clinical debut of its lead immune modulator. The modularity attracted Access Biotechnology to co-lead the round with Boxer Capital.
Additional new investors RA Capital and OrbiMed Advisors also participated in the round, as did existing investors Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, JDRF T1D Fund and BioInnovation Capital...